- Home
- FHTX vs LAB Comparison
FHTX vs LAB Comparison
Compare FHTX & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- LAB
- Stock Information
- Founded
- FHTX 2015
- LAB 1999
- Country
- FHTX United States
- LAB United States
- Employees
- FHTX N/A
- LAB N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- FHTX Health Care
- LAB Industrials
- Exchange
- FHTX Nasdaq
- LAB Nasdaq
- Market Cap
- FHTX 513.7M
- LAB 562.1M
- IPO Year
- FHTX 2020
- LAB 2011
- Fundamental
- Price
- FHTX $7.72
- LAB $1.62
- Analyst Decision
- FHTX Strong Buy
- LAB Strong Buy
- Analyst Count
- FHTX 5
- LAB 2
- Target Price
- FHTX $16.00
- LAB $2.88
- AVG Volume (30 Days)
- FHTX 131.6K
- LAB 2.8M
- Earning Date
- FHTX 11-04-2024
- LAB 10-30-2024
- Dividend Yield
- FHTX N/A
- LAB N/A
- EPS Growth
- FHTX N/A
- LAB N/A
- EPS
- FHTX N/A
- LAB N/A
- Revenue
- FHTX $25,515,000.00
- LAB $155,902,000.00
- Revenue This Year
- FHTX N/A
- LAB $62.60
- Revenue Next Year
- FHTX $8.77
- LAB $9.91
- P/E Ratio
- FHTX N/A
- LAB N/A
- Revenue Growth
- FHTX N/A
- LAB 48.23
- 52 Week Low
- FHTX $2.70
- LAB $1.21
- 52 Week High
- FHTX $10.25
- LAB $3.04
- Technical
- Relative Strength Index (RSI)
- FHTX 42.02
- LAB 39.48
- Support Level
- FHTX $7.33
- LAB $1.46
- Resistance Level
- FHTX $9.33
- LAB $1.69
- Average True Range (ATR)
- FHTX 0.72
- LAB 0.15
- MACD
- FHTX -0.13
- LAB -0.05
- Stochastic Oscillator
- FHTX 16.46
- LAB 18.60
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.